FY2030 Earnings Forecast for Arcellx Issued By HC Wainwright

Arcellx, Inc. (NASDAQ:ACLX) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for Arcellx in a note issued to investors on Monday, February 23rd. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of $4.95 for the year. HC Wainwright has a “Neutral” rating and a $115.00 price objective on the stock. The consensus estimate for Arcellx’s current full-year earnings is ($1.58) per share.

ACLX has been the subject of several other research reports. Stifel Nicolaus reiterated a “hold” rating and issued a $115.00 price objective (down from $127.00) on shares of Arcellx in a research report on Monday. UBS Group cut shares of Arcellx from a “buy” rating to a “neutral” rating and upped their price target for the stock from $100.00 to $115.00 in a research note on Tuesday. Truist Financial reiterated a “hold” rating and issued a $120.00 price objective (down from $134.00) on shares of Arcellx in a research note on Monday. Leerink Partners restated a “market perform” rating and set a $115.00 target price on shares of Arcellx in a research report on Tuesday. Finally, Evercore set a $115.00 price target on shares of Arcellx in a research report on Monday. One research analyst has rated the stock with a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $111.87.

Arcellx Trading Up 0.0%

Shares of ACLX stock opened at $113.76 on Tuesday. The company has a market capitalization of $6.58 billion, a P/E ratio of -28.95 and a beta of 0.36. The business’s 50 day moving average is $69.82 and its two-hundred day moving average is $75.65. Arcellx has a twelve month low of $47.86 and a twelve month high of $114.26.

Insider Activity

In related news, insider Christopher Heery sold 5,882 shares of the stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total transaction of $402,975.82. Following the completion of the sale, the insider owned 23,749 shares of the company’s stock, valued at approximately $1,627,043.99. This represents a 19.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 19,450 shares of company stock worth $1,283,477. 8.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arcellx

Several institutional investors have recently bought and sold shares of ACLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Arcellx by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company’s stock valued at $1,893,000 after acquiring an additional 1,390 shares during the period. Empowered Funds LLC purchased a new position in Arcellx in the first quarter valued at about $1,768,000. Intech Investment Management LLC raised its position in Arcellx by 27.7% in the first quarter. Intech Investment Management LLC now owns 21,967 shares of the company’s stock valued at $1,441,000 after purchasing an additional 4,760 shares during the period. Teacher Retirement System of Texas lifted its stake in shares of Arcellx by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 8,883 shares of the company’s stock worth $585,000 after purchasing an additional 151 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Arcellx in the second quarter worth about $563,000. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

Arcellx News Summary

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for up to $7.8 billion, a transformational M&A outcome that explains much of the upward price pressure by crystallizing acquisition value for ACLX shareholders. Gilead to buy Arcellx
• Neutral Sentiment: HC Wainwright published a FY2030 EPS projection (very bullish numerically) with a $115 price target but maintained a “Neutral” rating — the target is close to the current trade and offers limited additional upside. (Source: market research note)
• Neutral Sentiment: Short‑interest data reported for late February shows 0 shares and a 0.0 days‑to‑cover figure, which appears to be a data anomaly and therefore provides no clear signal about short‑seller pressure.
• Negative Sentiment: A broad set of sell‑side shops (Leerink, Evercore, Needham, Wells Fargo, Citigroup, Truist, Canaccord and others) moved ACLX toward “Hold” from stronger stances (strong‑buy/buy/outperform). Several firms cut or trimmed price targets (Truist cut to $120 from $134; others adjusted targets and ratings), creating short‑term headwinds and mixed sell signals despite the M&A news. Citigroup downgrades Arcellx Analyst coverage roundup

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.